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It has been increasingly recognised that recordings of the influence
on the patients general well-being or quality of life (QoL) are
important in randomised clinical trials designed to test the efficacy
of new treatments for cancer. The traditional physician-defined
endpoints such as survival, tumour response and toxicity have
been supplemented with patient-defined end-points, using instru-
ments such as the European Organisation of Research and
Treatment of Cancer Quality of Life Questionnaire (EORTC,
QLQ-C30) (Aaronson et al, 1993) and several others (de Haes 
et al, 1990; Schag et al, 1991; Cella et al, 1993). However, the use
of QoL assessments in clinical trials has been rather limited,
although increasing from 1.5 to 8.2% during 1980–1997 (Sanders
et al, 1998). QoL assessments are also in need of further method-
ological improvement before this endpoint can be regarded as
fully established with respect to its ability to provide unequivo-
cally useful data in clinical trials (Gunnars et al, 2001). 
QoL assessments are important not only in randomised clinical
trials, but also in the everyday clinical practice. For most patients
with advanced cancer, the primary goal of therapy is palliation,
and therefore it is particularly important to consider QoL factors in
the evaluation of these treatments (Guyatt et al, 1989). However,
Detmar et al (2000) found that only in a minority of cases did QoL
aspects play a significant role in the everyday clinical practice in
decisions of palliative chemotherapy. When asking oncologists,
the barriers to use QoL as a method of monitoring the response to
palliative treatment were time and resource constraints and
perceived lack of appropriate, clinically sound instruments
(Morris et al, 1998). 
Important reasons for difficulties in assessing QoL in clinical
trials involving patients with advanced cancer includes attrition
secondary to patient illness or death due to underlying malig-
nancy; ceiling effects of items and scales; content validity of
scales; and the possibility that our current methods are not sophis-
ticated enough to capture changes. The problems with attrition
also entail that the data will become more biased at each follow-up
because only survivors who have better QoL than the patients
dying or already dead are included. Attrition due to death or too
poor performance seems to be unavoidable, but strategies to
minimise the problem have been suggested (Bernhard et al, 1998).
Also, statistical methods to handle data that are missing not at
random are described, but are more complex compared to methods
for handling data missing at random (Troxel et al, 1998).
Understanding of how to effectively analyse and interpret data
from trials in patients with advanced cancer and present the data 
in a relevant fashion in order to guide researchers and clinicians
remain limited. A categorisation of whether a patient has benefited
from treatment, at least to a certain extent, in analogy with whether
an objective tumour regression (response) has occurred or not,
would facilitate understanding of QoL data from clinical trials. 
In 1993, Lydick and Epstein (1993) suggested an alternative to
traditional statistical methods of interpreting QoL data. They
recommended the use of an anchor-based interpretation of data
derived by QoL instruments by comparing changes in QoL data to
changes in other ratings or clinical changes. In addition, Sprangers
and colleagues (1999a) have recently recommended that researchers
who do not detect differences using core or disease-specific QoL
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subscales and single items considered to be of primary interest to
use as summary scores. 
In a series of trials recruiting patients with advanced sympto-
matic gastrointestinal cancers, who untreated have median
survivals of 2–5 months, we have explored the value of palliative
chemotherapy. The traditional, physician-defined endpoints, such
as survival and objective and subjective response rates, have been
supplemented with patient-defined endpoints. In the first trials,
mainly comprising patients with colorectal cancer, we used an
Uppsala questionnaire designed in 1985 (Glimelius et al, 1989,
1992, 1994), but have since 1992 gone over to the EORTC QLQ
C-30 (Aaronson et al, 1993) since this is an internationally tested
questionnaire. The difficulties with compliance, attrition,
complexity of the data and trade-off are, however, identical irre-
spective of which instrument is used. In order to increase our
knowledge about the possibilities of drawing conclusions from
QoL data of the patients, we have reanalysed the data from 2
randomised trials, one recruiting patients with pancreatic-biliary
cancer (Glimelius et al, 1996) and one patient suffering from
gastric cancer (Glimelius et al, 1997). In both trials, chemotherapy
and best supportive care (BSC) were compared with BSC alone.
The aims of the present study are 2-fold: (1) to explore meaningful
alternatives of analysing and interpreting QoL data to facilitate
detection of changes in QoL between treatment groups in patients
with advanced gastrointestinal cancer, and (2) to compare these
alternative methods of analysing and interpreting QoL data. 
PATIENTS AND METHODS 
Patients 
Between June 1992 and February 1995, a total of 120 patients
were recruited from 6 hospitals in Sweden for 2 parallel, multi-
centre randomised trials. The patients were either randomised to
immediate chemotherapy including BSC or to BSC only, with a
possibility for chemotherapy if BSC did not result in palliation. At
randomisation, 113 patients (94%) (44 pancreatic cancer, 26
biliary cancer, and 43 gastric cancer patients) completed the
EORTC QLQ-C30. Inclusion and exclusion criteria have been
described elsewhere (Glimelius et al, 1996, 1997). Selected patient
characteristics are presented in Table 1. 
Treatment 
For patients randomised to the chemotherapy group, the chemo-
therapy regimen was sequential 5-fluorouracil and leucovorin,
either alone (Nordic Gastrointestinal Tumor Adjuvant Therapy
Group, 1993) in patients above the age of 60 years with a Karnofsky
performance status (KPS) of 70 or less or combined with etoposide.
In gastric cancer patients, the ELF regimen (Wilke et al, 1991) was
used whereas in pancreatic or biliary cancer, a modification of ELF,
vizually FELv, was used (Glimelius et al, 1996).
Evaluation of treatment effects 
The evaluation of treatment effects followed a series of predeter-
mined analyses based upon prospective data recordings. These
included subjective response evaluations made by the treating
physician, and QoL evaluations using the EORTC QLQ-C30
version 1.0 (Aaronson et al, 1993; Fayers et al, 1995). The EORTC
QLQ-C30 was completed by the patients immediately prior to
randomisation and after 2 and 4 months prior to the tumour evalu-
ations. All scales were linearly transformed to a 0–100 scale. High
scores on the functional scales refer to a better level of functioning
while a higher score on the symptoms scale and single items
means that the patient is experiencing a higher degree of sympto-
matology. Missing values were handled as recommended by the
EORTC manual (Fayers et al, 1995), however, missing data were
infrequent as 80% or more of the items were completed by all
patients over the course of the study. 
The data from the EORTC QLQ-C30 were presented using the
traditional average global and scale scores (0–100) and four alter-
native methods. 
(1) A QoL rating was performed by 2 independent raters of the
average scale scores of the QLQ-C30. The raters were blind to
group assignment and all clinical information. The patients
were rated as ‘improved’, ‘unchanged’ or ‘worse’ compared to
the previous time. The criteria (Glimelius et al, 1996) were
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Table 1 Patient characteristics at randomisation 
Chemotherapy Best supportive care 
n 57 56 
Tumour site 
Pancreatic 24 20 
Biliary 12 14 
Gastric 22 21 
Age, median, (range) 64 (43–75) 64 (40–75) 
KPS, median (range) 80 (100–50) 80 (100–50) 
Type of symptoms 
Pain 32 33 
Weight loss 31 23 
Tiredness 25 16 
Nausea/vomiting 10 9 
Trouble swallowing 7 7 
Others 18 11 
Type of chemotherapy 
ELF 13 2 
FELv 27 0 
FLv 16 8 simple and agreement was high between the 2 raters (90%). In
the case of discrepancies, a consensus was reached through
discussions by the 2 raters. 
(2) Changes in global health status/QoL (composed by the 2
questions in the QLQ-C30) was based on at least half a stan-
dard deviation movement from baseline, as recommended to
be of clinical relevance (Lydick and Epstein, 1993; Juniper 
et al, 1994; Osboa et al, 1998). Depending upon the size and
direction of any change, a patient could receive either a rating
of ‘favourable’, ‘unfavourable’ or ‘unchanged’ at each time
interval. Patients from the upper and lower 15% of the sample
were scored as favourable or unfavourable, respectively, if
they continued to score in the upper or lower 15% at subse-
quent time intervals, even if their scores did not change by
more than half a standard deviation. 
(3) A summary score based on the sum of all items in the scale,
except the question regarding financial problems due to the
limited variance and low score of this item secondary to
Sweden’s health care system. From the sum of the 5 functional
scales and global health status/QoL score, where 100 is the
best score, the sum of the 3 symptom scales and 5 of the single
items, where 0 is the best score, was subtracted. The summary
score could range from a minimum of –800 to a maximum of
+600. In analogy with the categorisation performed for the
global health status/QoL, described above, a favourable
outcome was present if the scale scores remained above 450
(15% of patients had this score at baseline), or improved by at
least 100 points (1/2 SD was 102). If the summary score at
baseline was negative (15% had this at baseline, minimum
–289), the score had to be positive at the follow-up evaluation
in order to be classified as improved. Unchanged summary
scores were those scores that remained within +/– 100 points
and a worsening if the score decreased by more than 100
points or remained negative. 
(4) A limited QoL categorisation was based on the physical
functioning, emotional functioning, global health status/QoL
scales, and the sum of the symptoms scales which included
fatigue, nausea/vomiting, pain and the single items appetite
and diarrhoea. These scales were considered to be of greater
relevance than the others in advanced gastrointestinal cancer
treated with 5FU-based chemotherapy. To select particular
symptoms and single QoL items of primary interest in the
evaluation of QoL has been recommended (Bernhard et al,
1999; Sprangers et al, 1999a). The categorisation followed
principles used in the Clinical Benefit Response evaluation of
pancreatic cancer patients suggested by Rothenburg et al
(1996). A favourable outcome was present if the patient
improved in at least one of the domains (physical function by
at least 20 points, emotional functioning and global health
status/QoL by at least 17 points), and the sum of the symptoms
had decreased at least 50% or at least 50 points, if the sum was
initially below 100, without any negative change in any other
domain. A negative change was present in physical func-
tioning if the scale decreased by more than 20 points or to a
score of 20 points. Emotional functioning and global health
status/QoL was considered to be significantly deteriorated if it
decreased by 17 points or more and the sum of the symptoms
scales by 50 points or more. 
All patients who did not complete the QLQ-C30 at 2 and 4 months
were considered to have an unfavourable response on methods 1–4. 
Physician subjective ratings were recorded to provide subjective
information to contrast with the others methods of interpreting the
QLQ-C30 data. Based on personal interviews conducted at each
follow-up visit, which occurred every second or third week, the
treating physician gathered information from each patient
concerning: (a) presence of signs or symptoms secondary to the
tumour, (b) presence of symptoms associated with treatment toxi-
city and (c) KPS. The physician rated each patient, based on the
above criteria as either ‘symptom-free’, ‘improved’, ‘unchanged’
or ‘deteriorated’. The rating of ‘symptom-free or improved’ was
given if the patient reported no or decreased tumour-related symp-
toms, in the absence of any of the WHO subjective grade III or IV
treatment toxicities. 
Statistical analyses 
The evaluation of treatment effects followed a series of predeter-
mined analyses based on prospective data recordings. All analyses
were performed according to the ‘intention-to-treat’ principle.
Differences between proportions were tested using χ 2 analyses and
differences between means were tested using a 2-tailed Student t-
test. Significance testing of changes over time on the subgroups of
patients assessed at all time points was performed using 2-tailed
repeated measures analyses of variance (ANOVA). Cohen’s kappa
was used to calculate agreement between categorisations based
on the patient QoL scores and the physicians’ subjective ratings.
Survival differences were tested using the log-rank test. All statis-
tical analyses were performed using Statistica 4.1. 
RESULTS 
No significant differences in demographic information were found
between the chemotherapy and the BSC groups at randomisation.
The chemotherapy group had a median survival of 6 months
whereas the BSC group had a median survival of 3 months (log
rank test, P < 0.01). 
The BSC group had significantly greater attrition when
compared to the chemotherapy group (Table 2). After 2 months,
83% (45/54) of those interviewed at baseline completed the QLQ-
C30 in the chemotherapy group and 61% (32/52) in the BSC treat-
ment group. At 4 months, 50% (27/54) and 29% (15/52)
completed the QLQ-C30 in the chemotherapy and BSC treatment
group, respectively. In all but one patient, the reason for not
completing the QLQ-C30 at 2 and 4 months was secondary to
progressive disease with deterioration and inevitable death. Still
living patients (2 in each group at 2 months and 5 in each group at
4 months) who did not complete the QLQ-C30 at the scheduled
time had a range of survival of 2 to 38 days, median 8 days, after
scheduled assessment, and KPS of 70 to 20, median 50. Patients
who did not complete a questionnaire at 2 and 4 months were
considered to have an ‘unfavourable’ outcome using each of the
methods of analysing QoL. The physicians classified all these
patients as ‘worsened’. 
Use of the QLQ-C30 traditional average scale scores 
No significant differences between treatment groups were found
using the 5 functional scales, the global score, or the symptom
scales/items at randomisation, at 2 or 4 months (Table 2). In the
patients interviewed, all average scale scores remained at approxi-
mately the same level during the 4 months. However, when the
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3 times, a statistically significant decrease (P < 0.05) on the physical
functioning scale and a statistically significant increase (P < 0.05) on
the fatigue scale were seen for the BSC group (data not shown). 
Alternative methods of analysing the QLQ-C30 
Initial analyses demonstrated that no significant differences were
detected between the 2 randomisation groups when using the
global score of the QLQ-C30. However, when using the alterna-
tive methods of analysing QoL data, based on all patients who
answered the QLQ-C30 at randomisation, significantly higher
proportions of patients who were randomised to the chemotherapy
group had a favourable QoL when compared to the patients who
received BSC (Table 3). If estimations were based only on those
patients who answered the questionnaire after 2 or 4 months,
differences were statistically significant, between groups, for only
the QoL rating method (data not shown). 
Using Cohen’s kappa, a relatively high level of agreement was
found between the QoL rating and summary score (Cohen’s
kappa = 0.68; Table 4). However, the agreement between the
global health status/QoL score and summary scores was less
robust with a Cohen’s kappa coefficient of 0.45. 
Physician subjective ratings and agreements with the
alternative methods of analysing the QLQ-C30 
In the chemotherapy group, the treating physician considered 28
(52%) of the 54 patients answering the QLQ-C30 at randomisation
to have had either a continuously symptom-free period or
improved symptomatology in the absence of severe toxicity 2
months after randomisation (Table 3). The corresponding figure
after 4 months was 21 (39%) patients. These numbers were signif-
icantly lower in the BSC group. 
When the agreements between a subjective response and the
QoL assessments were tested, concordance was seen in most
patients using the QoL ratings (Cohen’s kappa = 0.82) where only
7 (9%) patients were categorised differently (Table 5). The agree-
ment between a subjective response and the limited QoL categori-
sation was also high (Cohen’s kappa = 0.79) whereas it was
moderate with the summary scores (Cohen’s kappa = 0.53) and
lower with global health status/QoL (Cohen’s kappa = 0.35). The
above pattern of results was similar at 4 months (data not
presented). The great number of discrepancies (25, 33%) seen
between a subjective response and changes in global health
status/QoL was mainly due to the fact that the latter scores often
remained unchanged. 
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Table 2 Quality of life scores (Sd) at randomisation (R) and at T1 (2 months) and T2 (4 months) in the chemotherapy and best
supportive care groups 
QLQ-C30 Scales/Items Chemotherapy Best supportive care
R T1 T2 R T1 T2 
Number of patients 54 45 27 52 32 15 
Functional scales 
Physical 74 (28) 72 (29) 69 (27) 74 (27) 67 (31) 73 (25) 
Role 56 (35) 66 (40) 58 (41) 70 (32) 63 (34) 72 (37) 
Emotional 65 (22) 75 (21) 75 (21) 68 (23) 65 (23) 66 (25) 
Cognitive 84 (18) 84 (21) 81 (20) 84 (20) 83 (21) 76 (26) 
Social 75 (30) 77 (29) 76 (31) 74 (29) 73 (32) 75 (30) 
Global health status 55 (18) 59 (23) 61 (20) 58 (22) 59 (26) 56 (22) 
Symptom scales/items 
Pain 32 (28) 20 (26) 21 (31) 24 (27) 26 (28) 25 (28) 
Fatigue 45 (30) 44 (27) 45 (29) 40 (30) 46 (33) 44 (25) 
Nausea/vomiting 21 (24) 19 (24) 23 (32) 15 (24) 24 (34) 22 (19) 
Dyspnoea 17 (27) 18 (22) 18 (27) 21 (25) 28 (31) 30 (26) 
Insomnia 30 (36) 18 (29) 14 (21) 32 (38) 27 (29) 27 (33) 
Constipation 23 (31) 14 (20) 19 (28) 22 (31) 31 (35) 19 (28) 
Diarrhoea 15 (26) 18 (30) 22 (32) 11 (21) 17 (26) 20 (21) 
Appetite 41 (37) 30 (34) 29 (36) 38 (37) 40 (39) 33 (36) 
Financial 4 (13) 7 (17) 8 (24) 5 (16) 7 (17) 20 (30) 
Summary score 207 (206) 254 (231) 222 (237) 236 (203) 215 (256) 268 (221) 
Table 3 Number (and proportions)a of patients with favourable quality of life response using different methods of
evaluating quality of life after 2 and 4 months of treatment 
Evaluation method Chemotherapy Best supportive care 
2 months 4 months 2 months 4 months 
Global health status 16 (29) 13 (24) 10 (20) 5 (10) 
QoL rating 24 (44**) 18 (33*) 10 (20) 6 (12) 
Summary score 21 (38*) 14 (25*) 7 (14) 5 (10) 
Limited QoL 27 (49*) 18 (33*) 13 (25) 6 (12) 
Physician rating 28 (52**) 21 (39*) 11 (21) 9 (17) 
a The figure within the parentheses refers to the percentage of responders based upon the number of patients
answering the QLQ-C30 at baseline. Statistical significance between the chemotherapy group and BSC group is
shown by *P < 0.05 and **P < 0.01. DISCUSSION 
In this exploratory study, we have used a commonly used ques-
tionnaire for cancer patients, the EORTC QLQ-C30 (Aaronson 
et al, 1993). We cannot have any opinion about whether other
instruments would have solved some of the problems in an easier
way. However, we believe that the problems encountered, and the
solutions suggested, are also relevant to other, presently available,
questionnaires. 
Global health status/QoL 
The traditional functional scales of the QLQ-C30, the global
health status/QoL score and any of the symptom scales, could not
effectively detect differences between treatment groups. The
EORTC group recommends that the ‘Global Health Status/QoL’
scale is used as an overall summary measure (Fayers et al, 1995).
This scale is capable of distinguishing between groups of patients
assumed to differ in their overall QoL and to respond to changes in
the health status (Bergman et al, 1991; Bjordal and Kaasa, 1992;
Aaronson et al, 1993; Sigurdadóttir et al, 1996; Curran et al, 1997).
Based upon the experiences of these 2 trials, this scale is, however,
not sufficiently sensitive to provide relevant information about
changes in several patients. The changes that were seen occurred
more often in the question about ‘overall physical condition’ and
not in the one about ‘overall quality of life’. It is therefore unlikely
that the modification made in later versions of QLQ-C30,
replacing the question about ‘overall physical condition’ with
‘overall health’, will improve the ability to detect the changes
(Fayers et al, 1995). With the criteria that the scores should change
by more than one step (out of 12 steps) and exceed half a SD in
order to be clinically relevant, many patients showed no change
(even if a change appeared to be evident clinically and/or based
upon the answers to the other questions of the questionnaire).
There are different explanations for this apparent discrepancy,
either that the 2 questions constituting the scale cannot identify the
changes, or that no true changes occurred. Alternatively, the
changes in performance and symptomatology we, as health profes-
sionals, register, and the patients themselves record in the
remaining 28 questions, may not influence overall QoL. The posi-
tive and sometimes dramatic changes that may be seen in tumour-
related symptoms together with improvements in several functions
do not alleviate the severity of the disease and its ultimate
outcome, with no comparative change in overall QoL, or,
conversely, the patients’ abilities to adequately cope with the nega-
tive changes that may accompany disease progression and/or that
follows severe adverse effects may keep the overall QoL relatively
stable. Patients may also shift their internal standards and values,
or conceptualisation of perceived QoL, in addition to actual health
state. This phenomenon, called response shift, is of fundamental
importance to social and medical science (Sprangers and
Schwartz, 1999). There is much evidence in the literature of para-
doxical and counter-intrusive findings, which can be explained in
terms of response shift. Patients with life-threatening diseases or
disabilities report stable QoL (Andrykowski et al, 1993). Also,
people with a severe chronic illness report the same levels of QoL
as less severely ill patients and healthy persons (Cassileth et al,
1984; Breetvelt and Van Dam, 1991; Sprangers et al, 1999b). We
have no method of identifying which of the above mentioned
explanations prevail. 
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Table 4 Agreement between the QoL rating, global health status/QoL and summary scores 
QoL rating Summary score 
Improved Unchanged Worse Total 
Improved 28 6 0 34
Unchanged 4 12 5 21
Worse 1 0 21 22
Total 33 18 26 77
Cohen’s kappa = 0.68 
Global health status/QoL Summary score 
Improved Unchanged Worse Total 
Improved 23 5 2 30
Unchanged 10 11 10 31
Worse 0 1 15 16
Total 33 18 26 77
Cohen’s kappa = 0.45 
Table 5 Agreement between the physician subjective ratings and quality of life evaluations 
QoL rating Global health status Summary score Limited QoL 
Favour Unfav Favour Unfav Favour Unfav Favour Unfav 
Physician
Favourable 33 6 22 17 27 12 35 4 
Unfavourable 1 37 8 30 6 32 5 33 
Total 34 43 30 47 33 44 40 27 
Cohen’s kappa 0.82 0.35 0.53 0.79 Alternative methods of analysing QLQ C-30 
Rather than rely only on the patients’ own perception of the
‘Global Health Status/QoL’ summary score, it appears important
to use all, or at least most of, the information provided by the
patients order to evaluate whether, and to what extent, the patient
improves/continues to do well subsequent to an intervention.
Alternative methods of scoring QoL data were thus tested. Each of
the alternative methods successfully detected differences between
treatment groups. It has been suggested that the individual patient
should vary the weights that they attach to different aspects of life
since QoL is highly individual (O’Boyle et al, 1992; Campell and
Whyte, 1999). However, this approach is time and resource inten-
sive and the effects of a treatment on a specific aspect can only be
assessed for those patients choosing that area. In addition, the type
and severity of symptoms caused by the disease and the treat-
ments, the way patients react to their diagnosis, how they interact
with relatives and friends and how their existential well-being is
affected vary from individual to individual. Most of us accept that
we cannot add up scores from different dimensions of a complex
health profile (Cox et al, 1992). Yet, since in practice, improve-
ments in some domains, but losses in others are seen in individual
patients, we have to come up with practical solutions so that QoL
measurements provide information that can facilitate the drawing
of proper conclusions. We have in this paper described 3 ways of
summarising the information in the questionnaire. 
QoL rating: By using an older questionnaire, centred around
problems such as pain, tiredness and distress in daily situations
together with questions about existential well-being (Kaasa et al,
1988), we obtained good experience by allowing 2 raters to cate-
gorise a response based upon the scores at randomisation and
during follow-up (Glimelius et al, 1989, 1994). Provided this
rating is performed blindly as regards other information it provides
an unbiased comparison of the outcome based upon the patients’
own answers. In typical patients, when either a clear improvement,
or a similarly clear deterioration, is seen in several aspects, this
rating is very simple. In other instances, where the changes are
small or particularly when they move in different directions, the
rating may be difficult, and open for criticism in individual
patients. When using the older instrument in patients with
colorectal cancer, we found that the rating was easy in most
patients (Glimelius et al, 1989, 1994). Using EORTC QLQ-C30,
the rating was also straightforward in most patients with pancre-
atic and biliary cancer (Glimelius et al, 1996) but more often diffi-
cult in gastric cancer patients (Glimelius et al, 1997). This can, at
least partially, be anticipated in the light of their differences in
response to chemotherapy (Ross et al, 1997). 
Summary score: Even if the blinded QoL ratings give an
adequate, unbiased discrimination between the 2 groups, they are
hampered by not being precisely defined and resource demanding.
However, we do not find that the ratings are more uncertain than
the objective response evaluation made by 2 independent radiolo-
gists on the bases of serial X-ray examinations (Labianca et al,
1996). More precise, and mathematically defined, criteria would
have at least practical advantages. Although every type of recom-
bination requires sets of weights (Cox et al, 1992; Matthews,
1993), the most simple and robust way is to make an unweighted
sum of all scores. This is conceptually wrong, since all items are
not equally important and all scales are not equally graded. The
categorisation based upon the unweighted summation of all scores
correlated well with the QoL rating, it showed a high agreement
with the subjective response evaluation made by the physician,
and it discriminated between the 2 groups. Therefore, it appears to
be sufficiently reliable and valid to be used. Further analyses,
however, illustrated that a weighting would provide more accurate
estimates (data not shown). Some scales, like the role functioning
scale (RF), appeared less relevant. These scales contained fewer
levels (3 or 4 compared with 8 to > 10 for the others), thereby actu-
ally increasing their relative importance. In order to illustrate the
relevance of weights, we arbitrarily reduced the relative influence
of the RF scale by 50%. This simple manoeuvre reduced the
problem substantially. It is likely that more accurate weights could
be created, but we chose not to continue. The RF scale has been
reformulated in later versions of the QLQ C-30 (Fayers et al,
1995). The inherent difficulties involved in the use of weights also
prevented us from proceeding (Schipper, 1990; Cox et al, 1992;
Matthews, 1993). 
Limited QoL categorisation: 4 domains (physical functioning,
emotional functioning, global health status/QoL and specific
symptoms) were considered to be relatively more important in
regard to potential differences between the treatment groups. An
overall favourable outcome was analogous with the idea of a clin-
ical benefit response (Rothenberg et al, 1996), considered to be
present if the patient improved in at least one important aspect
without deteriorating in others. The limited QoL categorisation
could also successfully detect differences between treatment
groups. It can be expected that the use of the limited QoL categori-
sation may result in more accurate detection of changes in QoL as
it covers more aspects of patients’ well being than the clinical
benefit response rating. Furthermore, it is entirely defined by the
patient and not a mixture of patient-defined and physician-defined
endpoints. Liabilities of using the limited QoL categorisation are
that it excludes some items that may be relevant for certain
patients. Similar to the summary score, the limited QoL categori-
sation also is not conceptually adequate in explaining changes in
QoL for individual patients, since no weights are utilised. 
It can be concluded that the alternative methods of analysing the
QLQ C-30 described here could discriminate between the 2
randomisation groups. A high agreement between the scales and
with the subjective evaluation made by the physician were found.
The agreements were also qualitatively the same in the 2 randomi-
sation groups. We can not state whether one method is superior to
any of the others, although it would appear as though the summary
scores are less accurate than the others. It is, however, the simplest
one to calculate. The patients’ own summary, ‘Global health
status/QoL’ was less discriminatory than either of the summary
measures. More rigorous and empirically grounded procedures are
needed for generating questionnaire summary scores and decision
rules for classifying individual patients as QoL responders versus
non-responders. The arbitrary scoring procedures employed here
were then used for illustrative purposes only. 
Problems with compliance and attrition 
Compliance with completing the questionnaire was in these
studies no major problem, probably due to a long tradition to
include QoL measurements in the trials and close monitoring by a
research nurse. The difficulties to obtain completed questionnaires
from patients with progressive disease and, thus, the poorest
performance status, remain. If this drop-out can not be kept at a
low level, it will disturb the analyses because of under-reporting of
worsening QoL. Considerably lower levels of compliance have
been reported in other studies (Fayers et al, 1997). 
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are well illustrated in this study. Analyses of the average scores in
interviewed patients will thus not reflect the outcome of the
randomised population, but rather only those who make it to the
next evaluation in a general condition good enough to complete
the questionnaire. 
This selective drop-out has been discussed by several
researchers, and different analytic techniques have been suggested
(Diggle and Kenward, 1994; Hopwood et al, 1994; Molenberghs 
et al, 1997; Moinpour et al, 2000). When reporting the results of
the randomised trials, and used in this exploratory study, we chose
to perform a categorisation of the patients into those with a
favourable and those with an unfavourable QoL outcome. Non-
interviewed patients were then all classified as non-responders. We
did then not assign a particular QoL score to non-interviewed
patients, and compared average scores for interviewed and non-
interviewed patients, but rather based the categorisation upon the
observation that non-interviewed patients were dead or terminally
ill from the disease, i.e. they did not have a favourable outcome. A
practical solution to the problem of this selective and thus poten-
tially informative drop-out is to present data in different ways, and
then discuss their relevance (Hopwood et al, 1994). For example,
as can be seen in Table 2, the average scores during follow-up did
not differ between the groups. When categorised, no differences
were again seen if the proportion of responders was based only
upon those interviewed (data not shown), whereas differences
were seen if based upon all randomised patients (see Table 3). The
conclusions are that chemotherapy with BSC is superior to BSC
since more patients will have a favourable QoL outcome. They
also live longer, and the average QoL during those extra months is,
at least, not inferior to those experienced in the BSC group. 
Conclusions 
The difficulties to obtain completed questionnaires in trials from
patients with progressive disease will likely remain. A possible
solution is to use a categorisation of patients into those with a
favourable and those with an unfavourable QoL outcome and 
non-interviewed patients will be classified as non-responders.
Although we can see advantages and disadvantages with each of
the 3 alternative methods, they all appear to be useful for this
purpose in patients with advanced cancers. For practical reasons,
we do not advocate the QoL rating in large randomised trials.
Although the limited QoL categorisation and summary score are
not conceptually correct when interpreting individual patient’s
QoL, the use of these methods when assessing differences between
treatment groups may prove to be beneficial. Research is
warranted to replicate the findings as well as test similar methods
of interpreting QoL in patients with advanced cancer at other sites. 
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